65 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
42
Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.
Max Planck Institute of Psychiatry
19
Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands.
Max Planck Institute of Psychiatry
27
Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.
Max Institute of Psychiatry
17
Structure-based design of novel, urea-containing FKBP12 inhibitors.
Agouron Pharmaceuticals
6
High-affinity FKBP-12 ligands derived from (R)-()-carvone. Synthesis and evaluation of FK506 pyranose ring replacements
TBA
129
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol Myers Squibb
28
Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52.
Max Planck Institute of Psychiatry
41
Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52.
Max Planck Institute of Psychiatry
14
Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.
University of Wu£Rzburg
17
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
The Scripps Research Institute
2
Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.
Novartis Pharma
8
Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands
TBA
8
Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin
TBA
15
Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-O-desmethyl ascomycin)
TBA
4
Alkyl ether analogs of the FK-506 related, immunosuppressive macrolide L-683,590 (ascomycin)
TBA
4
The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506
TBA
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
3
Antascomicin B stabilizes FKBP51-Akt1 complexes as a molecular glue.
Technical University Darmstadt
88
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
University of California San Diego
19
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
Sichuan University
15
Macrocyclization strategy for improving candidate profiles in medicinal chemistry.
Gachon University
3
Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties.
Biocon Bristol-Myers Squibb R&D Centre
31
Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.
University of Michigan
10
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation.
Second Military Medical University (Naval Medical University)
103
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).
University of Hradec Kralove
35
Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
Technical University Darmstadt
10
Regulation of gene expression by synthetic dimerizers with novel specificity.
Ariad Gene Therapeutics
9
Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.
University of W£Rzburg
3
Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress.
Universidad Del Pa£S Vasco Upv/Ehu
11
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Guilford Pharmaceuticals
53
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.
Guilford Pharmaceuticals
40
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Guilford Pharmaceuticals
5
Antifungal rapamycin analogues with reduced immunosuppressive activity.
Abbott Laboratories
4
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay.
Bristol Myers Squibb
20
Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket.
Ariad Gene Therapeutics
4
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
Abbott Laboratories
10
Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties.
Max-Planck Research Unit
11
Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity.
Merck Research Laboratories
5
C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.
Merck Research Laboratories
87
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol Myers Squibb
5
C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.
Merck Research Laboratories
20
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Eberhard Karls University T£Bingen
6
Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.
Yale University
27
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
Abbott Laboratories
19
Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins.
Max Planck Institute of Psychiatry
12
2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
Topadur Pharma
38
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
Arbutus Biopharma
73
Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof
Pharmablock Sciences (Nanjing)
7
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
University of Illinois At Chicago